Scientists move one step closer in the battle against fatty liver disease. Researchers at Michigan Medicine developed a glycine-based tripeptide to treat the severe form of fatty liver disease called nonalcoholic steatohepatitis. Researchers hope this discovery is effective in human trials to offset the ever-worldwide spread of the consideration.
